MAIA Biotechnology completed a $30 million equity raise and announced 2026 strategic milestones including Phase 3 trial progress for its ateganosine cancer therapy. The company secured FDA Fast Track designation and reported positive Phase 2 data showing median PFS of 5.6 months and OS of 17.8 months. Diamond Equity Research maintains a $10.27 pe...

MAIA Biotechnology, Inc. announced the successful closing of an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. The company plans to use net proceeds for clinical trials and general corporate purposes.

MAIA Biotechnology priced an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. Net proceeds will be used for clinical trials and general corporate purposes. The offering is expected to close on March 4...

MAIA Biotechnology announced an underwritten public offering of common stock and pre-funded warrants, with Konik Capital Partners LLC serving as sole book-running manager. The company intends to use net proceeds for clinical trials and general corporate purposes. MAIA's lead program, ateganosine (THIO), is a potential first-in-class cancer telome...

The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significan...